Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 102-108

  Lee, Seung Hyeun ^a   Noh, Kyung Bo ^b   Lee, Ji Sung ^a   Lee, Eun Joo ^a   Min, Kyung Hoon ^a   Hur, Gyu Young ^a   Lee, Seung Heon ^a   Lee, Sung Yong ^a   Kim, Je Hyeong ^a   Lee, Sang Yeub ^a   Shin, Chol ^a   Shim, Jae Jeong ^a   Kim, Chul Hwan ^a   Kang, Kyung Ho ^a   In, Kwang Ho ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University Ansan Hospital   (South Korea)

Author keywords

Chemotherapy; ERCC1; Predictive marker; Pulmonary adenocarcinoma; Thymidylate synthase

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FOLIC ACID; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RESPONSE RATE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CISPLATIN; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 84878973389     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.002     Document Type: Article

References (41)

1. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
3. Grossi F., Aita M., Defferrari C., Rosetti F., Brianti A., Fasola G., et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009, 14:497-510.
4. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
5. Joerger M., Omlin A., Cerny T., Fruh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets 2010, 11:37-47.
6. Yeh K.H., Shun C.T., Chen C.L., Lin J.T., Lee W.J., Lee P.H., et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998, 82:1626-1631.
7. Harpole D.H., Moore M.B., Herndon J.E., Aloia T., D'Amico T.A., Sporn T., et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001, 7:562-569.
8. Edler D., Kressner U., Ragnhammar P., Johnston P.G., Magnusson I., Glimelius B., et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000, 6:488-492.
9. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005, 92:1231-1239.
10. Shimokawa H., Uramoto H., Onitsuka T., Iwata T., Nakagawa M., Ono K., et al. TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 2011, 72:360-364.
11. Bepler G., Sommers K.E., Cantor A., Li X., Sharma A., Williams C., et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3:1112-1118.
12. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
13. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
14. Monica V., Scagliotti G.V., Ceppi P., Righi L., Cambieri A., Lo Iacono M., et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009, 15:7547-7552.
15. Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999, 59:3968-3971.
16. Altaha R., Liang X., Yu J.J., Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004, 14:959-970.
17. Joshi M.B., Shirota Y., Danenberg K.D., Conlon D.H., Salonga D.S., Herndon J.E., et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005, 11:2215-2221.
18. Rosell R., Lord R.V., Taron M., Reguart N. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002, 38:217-227.
19. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
20. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
21. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
22. Simon G.R., Sharma S., Cantor A., Smith P., Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127:978-983.
23. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
24. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
25. Wu M.F., Hsiao Y.M., Huang C.F., Huang Y.H., Yang W.J., Chan H.W., et al. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 2010, 5:1143-1151.
26. Takezawa K., Okamoto I., Okamoto W., Takeda M., Sakai K., Tsukioka S., et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011, 104:1594-1601.
27. Chen C.Y., Chang Y.L., Shih J.Y., Lin J.W., Chen K.Y., Yang C.H., et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011, 74:132-138.
28. Sun J.M., Han J., Ahn J.S., Park K., Ahn M.J. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011, 6:1392-1399.
29. Chang M.H., Ahn J.S., Lee J., Kim K.H., Park Y.H., Han J., et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010, 69:323-329.
30. Zucali P.A., Giovannetti E., Destro A., Mencoboni M., Ceresoli G.L., Gianoncelli L., et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 2011, 17:2581-2590.
31. Karlberg M., Ohrling K., Edler D., Hallstrom M., Ullen H., Ragnhammar P. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res 2010, 30:645-651.
32. Zamble D.B., Mu D., Reardon J.T., Sancar A., Lippard S.J. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
33. Kwon H.C., Roh M.S., Oh S.Y., Kim S.H., Kim M.C., Kim J.S., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007, 18:504-509.
34. Bhagwat N.R., Roginskaya V.Y., Acquafondata M.B., Dhir R., Wood R.D., Niedernhofer L.J. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 2009, 69:6831-6838.
35. Niedernhofer L.J., Bhagwat N., Wood R.D. ERCC1 and non-small-cell lung cancer. N Engl J Med 2007, 356:2538-2540. author reply 40-1.
36. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
37. Roth J.A., Carlson J.J. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 2011, 12:393-401.
38. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D., Groshen S., Lenz H.J. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002, 17:46-49.
39. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
40. Takehara A., Kawakami K., Ohta N., Oyama K., Ota Y., Oda M., et al. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res 2005, 25:4455-4461.
41. Wei S.Z., Zhan P., Shi M.Q., Shi Y., Qian Q., Yu L.K., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011, 28:315-321.